CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. Prevention of skin cancer and reduction of keratotic skin lesions during ...
A major cause of treatment failure in patients undergoing stem cell transplantation for malignancies is disease recurrence. Contaminated stem cell harvests have been suggested as one of the possible ...
October 24, 2011 — In nonstraightforward bone marrow analysis, the presence of 30% or more CD34+ megakaryocytes is a strong indicator of megaloblastic anemia or a myeloid neoplasm, according to a ...
Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461 Thirteen patients (MM, n = 7; NHL, n = 6) ...
Immunofluorescence detection of the complement split product C4d along peritubular capillaries in renal allograft biopsies is the mainstay for the diagnosis of antibody-mediated rejection. The extent ...
Expanding on the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutchinson Cancer Center’s expertise in providing Human CD34+ HSPCs, we have established a high-efficiency and ...
We've had the opportunity to evaluate the CD34+ cell in the past 20 years, and finally we have a tool that represents a potential breakthrough for patients with CMD, said Douglas Losordo, MD, FACC, ...
Epoch-Making Breakthrough of the Stem-Cell Nutritional Supplementation CD34 Nu-Signals®, Currently Undergoing Rigorous Clinical Trials Conducted by Prestigious Medical Institutions to Validate Its ...
Polycythemia vera is the ultimate phenotypic consequence of the V617F mutation in Janus kinase 2 (encoded by JAK2), but the extent to which this mutation influences the behavior of the involved CD34+ ...
CAMBRIDGE, Mass. & HAIFA, Israel--(BUSINESS WIRE)--Minovia Therapeutics, a clinical-stage company focused on the development of cell-based Mitochondrial Augmentation Technology (MAT) to treat ...
The FDA granted accelerated approval to Kresladi for the treatment of pediatric patients with severe LAD-I due to biallelic variants in ITGB2 without an available HLA-matched sibling donor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results